Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

libragen Celebrates Success in European PolyModE Project

Published: Tuesday, October 01, 2013
Last Updated: Tuesday, October 01, 2013
Bookmark and Share
Biocatalysis and metagenomics used for generation of improved hydrocolloids with potential therapeutic properties.

libragen has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.

libragen is internationally recognized for its expertise in biocatalysis and metagenomics (the study of whole genetic material from environmental samples) and is regularly engaged as a partner in such large research programs. As a key member of this collaboration - which included both academic and industrial partners - libragen successfully developed a high-throughput functional screen for the detection of sulphatase activity and metagenomic screening libraries using environmental samples. As a result of this combined approach, 10 novel sulphatase producers were identified from more than 20000 screened metagenomic clones and the partners triumphed in identifying, characterizing and optimizing novel enzymes for the modification of all six targeted polysaccharides overall.

libragen’s biocatalysis project leader, Dr. Rob Ter Halle, will be presenting how biocatalysis offers significant advantages in comparison to classical chemistry in terms of selectivity, specificity and yield, on 10 October at 14:00 at the Industrial Biotech Forum during Biotechnica 2013, Hannover, (8-10 October). His talk, entitled “Applied biocatalysis to obtain novel glyco-conjugates”, will detail how libragen’s bespoke contract research services increased both manufacturing profitability and competitiveness in the context of a real-world example – the synthesis of the cosmetic ingredient glucosyl conjugate of caffeic acid. In this example, libragen’s advanced technology and expertise yielded a remarkably efficient process founded on the principles of green chemistry. Only water was used as a solvent, no derivatization was required and all reagents were obtained from natural, renewable sources. The end-product has vastly improved solubility and oxidative stability compared to caffeic acid, yielding a higher performance compound that is now efficiently produced at a scale of several hundred kilos, while saving both time and money.

Biotechnica delegates can also visit booth E59 to discover how libragen’s expertise in biocatalysis and metagenomic technologies can be applied to enhance their specific application.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!